ARGENX SE ARGX

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating income $1.05B-$21.7M-$425.0M-$720.3M-$348.7M-$477.6M-$198.9M-$81.8M—
Net income $1.29B$833.0M-$295.1M-$709.6M-$408.3M-$608.5M-$181.2M-$66.6M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets $8.68B$6.20B$4.54B$3.13B$2.85B$2.28B$1.61B——
Total equity $7.32B$5.50B$4.10B$2.81B$2.53B$1.67B$1.18B$616.5M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001697862-26-000032.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Total equity
  • Total current liabilities
  • Total current assets
Total equity, Total current liabilities, Total current assets by fiscal year, in US dollars The same figures are in the table below this chart. 0 2B 4B 6B 8B Total equity, FY2018: 616.5M Total equity, FY2019: 1.2B Total equity, FY2020: 1.7B Total equity, FY2021: 2.5B Total equity, FY2022: 2.8B Total equity, FY2023: 4.1B Total equity, FY2024: 5.5B Total equity, FY2025: 7.3B FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Total equity — $616.5M $1.18B $1.67B $2.53B $2.81B $4.10B $5.50B $7.32B
Total current liabilities — — — — — — — — —
Total current assets — — — — — — — — —

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $236.38B 30.7x 10.0%
GILD GILEAD SCIENCES, INC. $187.23B 22.3x 2.4%
MRNA Moderna, Inc. $58.11B — -39.9%
RVMD Revolution Medicines, Inc. $45.01B — —
BIIB BIOGEN INC. $32.60B 25.1x 2.2%
SCNI Scinai Immunotherapeutics Ltd. $25.80B — 99.2%
NBIX NEUROCRINE BIOSCIENCES INC $15.82B 33.3x 21.4%
EXEL EXELIXIS, INC. $14.62B 21.2x 7.0%